The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.
news, journals and articles from all over the world.
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.